Pancreatic Cancer Research

ResearcherLoma Linda UniversityActive in the last 2 years

Ryan N. Fuller

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7067-4500; OpenAlex author ID A5053009470. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: 2 papers

Papers 4

  1. Small non-coding RNAs and pancreatic ductal adenocarcinoma: Linking diagnosis, pathogenesis, drug resistance, and therapeutic potential. Co-author DOI 10.1016/j.bbcan.2024.189153↗
  2. miRNA signatures underlie chemoresistance in the gemcitabine-resistant pancreatic ductal adenocarcinoma cell line MIA PaCa-2 GR. Co-author DOI 10.3389/fgene.2024.1393353↗
  3. Pancreatic Cancer Health Disparity: Pharmacologic Anthropology. First author DOI 10.3390/cancers15205070↗
  4. Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine. Co-author DOI 10.2147/ott.s341720↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nathan R. Wall · 4 shared papers, 2022–2024 · strength 1.00
  2. Marino A. De León · 1 shared paper, 2023 · strength 0.26
  3. Charles Wang · 1 shared paper, 2024 · strength 0.26
  4. Tiantian Liu · 1 shared paper, 2024 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.